Compare Piramal Enterprises with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x -36.5 133.5 - View Chart
P/BV x 1.2 3.1 40.2% View Chart
Dividend Yield % 1.9 0.7 270.7%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
SUN PHARMA
Mar-20
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303484 682.2%   
Low Rs1,797315 570.1%   
Sales per share (Unadj.) Rs716.5136.9 523.5%  
Earnings per share (Unadj.) Rs79.717.5 456.7%  
Cash flow per share (Unadj.) Rs107.926.0 414.9%  
Dividends per share (Unadj.) Rs28.004.00 700.0%  
Dividend yield (eoy) %1.11.0 109.7%  
Book value per share (Unadj.) Rs1,477.5188.7 783.2%  
Shares outstanding (eoy) m184.452,399.26 7.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.62.9 121.9%   
Avg P/E ratio x32.022.9 139.7%  
P/CF ratio (eoy) x23.615.4 153.8%  
Price / Book Value ratio x1.72.1 81.5%  
Dividend payout %35.122.9 153.3%   
Avg Mkt Cap Rs m470,292958,864 49.0%   
No. of employees `0007.817.8 44.0%   
Total wages/salary Rs m22,50463,624 35.4%   
Avg. sales/employee Rs Th16,899.418,490.6 91.4%   
Avg. wages/employee Rs Th2,877.73,582.6 80.3%   
Avg. net profit/employee Rs Th1,879.92,357.6 79.7%   
INCOME DATA
Net Sales Rs m132,153328,375 40.2%  
Other income Rs m3,1286,360 49.2%   
Total revenues Rs m135,281334,735 40.4%   
Gross profit Rs m66,29069,898 94.8%  
Depreciation Rs m5,20220,528 25.3%   
Interest Rs m44,0973,027 1,456.7%   
Profit before tax Rs m20,11952,702 38.2%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m8,6118,228 104.7%   
Profit after tax Rs m14,70141,868 35.1%  
Gross profit margin %50.221.3 235.7%  
Effective tax rate %42.815.6 274.2%   
Net profit margin %11.112.8 87.2%  
BALANCE SHEET DATA
Current assets Rs m122,742316,542 38.8%   
Current liabilities Rs m310,810157,064 197.9%   
Net working cap to sales %-142.348.6 -293.0%  
Current ratio x0.42.0 19.6%  
Inventory Days Days2388 26.4%  
Debtors Days Days39105 37.1%  
Net fixed assets Rs m116,904243,102 48.1%   
Share capital Rs m3692,399 15.4%   
"Free" reserves Rs m272,161450,245 60.4%   
Net worth Rs m272,530452,645 60.2%   
Long term debt Rs m270,19620,289 1,331.7%   
Total assets Rs m856,261682,525 125.5%  
Interest coverage x1.518.4 7.9%   
Debt to equity ratio x1.00 2,211.9%  
Sales to assets ratio x0.20.5 32.1%   
Return on assets %6.96.6 104.4%  
Return on equity %5.49.2 58.3%  
Return on capital %12.411.2 110.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20074,219 20.5%   
Fx outflow Rs m4,88927,964 17.5%   
Net fx Rs m10,31246,255 22.3%   
CASH FLOW
From Operations Rs m-115,97565,548 -176.9%  
From Investments Rs m-8,265-25,888 31.9%  
From Financial Activity Rs m107,525-57,151 -188.1%  
Net Cashflow Rs m-16,650-13,857 120.2%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jan 22, 2021 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS